SP 1 303
Alternative Names: SP-1-303Latest Information Update: 13 Sep 2023
Price :
$50 *
At a glance
- Originator Shuttle Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Ataxia telangiectasia mutated protein stimulants; HDAC1 protein inhibitors; HDAC3 protein inhibitors; HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 11 Sep 2023 Shuttle Pharmaceuticals receives a issuance of a Canadian patent for its histone deacetylase (HDAC) inhibitor platform
- 28 Mar 2023 Shuttle Pharmaceuticals plans IND enabling for Breast cancer (Shuttle Pharmaceuticals pipeline, March 2023)
- 22 Mar 2023 Preclinical trials in Breast cancer in USA (unspecified route) (Shuttle Pharmaceuticals pipeline, March 2023)